Skip to content
Study details
Enrolling now

MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer

Mayo Clinic
NCT IDNCT05438563ClinicalTrials.gov data as of Apr 2026
Target enrollment

100

Study length

about 4.9 years

Ages

45–80

Sex

Male only

Locations

1 site in MN

What this study is about

This trial is testing whether MRI-guided transurethral ultrasound ablation (TULSA) can safely and effectively treat low to intermediate grade prostate cancer. TULSA is a minimally invasive procedure that uses ultrasound guided by MRI to destroy tumor cells in the prostate.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Questionnaire Administration
  • 2.Undergo Biopsy
  • 3.Undergo Bone Scan
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change in quality of life, Metastasis-free survival, Multiparametric magnetic resonance imaging (mpMRI) Prostate Imaging and Reporting and Data System (PI-RADS) version 2 score for each visible lesion, Overall survival

Procedures

biopsy, imaging, endoscopy

Body systems

Oncology